title: Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
abstract: BACKGROUND
  Although the vaccine research and development network in the United States remains vibrant, its continued success requires maintaining harmonious interaction among its many components. Changing one component is likely to affect the system overall. An examination of case studies of the development of selected vaccines would allow an examination of the network as a whole. This article presents conclusions drawn from the case study review undertaken.
  
  
  OBJECTIVE
  Successful development of vaccines is a time-intensive process requiring years of commitment from a network of scientists and a continuum of regulatory and manufacturing entities. We undertook this work to shed light on how well the vaccine development system in the United States performs.
  
  
  METHODS
  The National Vaccine Advisory Committee examined the research and development pathways of several vaccines that reached licensure expeditiously (hepatitis B vaccine, Haemophilus influenzae type b conjugate vaccines); some that became licensed only after considerable delay (oral typhoid Ty21a vaccine, varicella vaccine); some that are at the point of imminent or recent licensure (reassortant Rhesus rotavirus vaccine, which was licensed by the Food and Drug Administration on August 30, 1998) or near submission for licensure (intranasal cold adapted influenza vaccine); and one for which clinical development is slow because of hurdles that must be overcome (respiratory syncytial virus vaccines).
  
  
  RESULTS
  Some common themes emerged from the reviews of these vaccine "case histories": the expediting influence of a strong scientific base and rationale; the need for firm quantitation of disease burden and clear identification of target populations; the critical role played by individuals or teams who act as "champions" to overcome the inevitable obstacles; availability of relevant animal models, high-quality reagents and standardized assays to measure immune response; the absolute requirement for well designed, meticulously executed clinical trials of vaccine safety, immunogenicity, and efficacy; postlicensure measurements of the public health impact of the vaccine and a track record of the vaccine's safety and acceptance with large-scale use; and the critical need for international collaborations to evaluate vaccines against diseases of global importance that are rare in the United States (eg, typhoid fever). It was clear that the critical step-up from bench scale to pilot lots and then to large-scale production, which depends on a small group of highly trained individuals, is often a particularly vulnerable point in the development process.
  
  
  CONCLUSIONS
  One fundamental lesson learned is that within the varied and comprehensive US vaccine development infrastructure, multiple and rather distinct paths can be followed to reach vaccine licensure. The National Vaccine Advisory Committee review process should be conducted periodically in the future to ascertain that the US vaccine development network, which has been enormously productive heretofore and has played a leadership role globally, is adapting appropriately to ensure that new, safe, and efficacious vaccines become available in a timely manner.
authors.affiliation: National Vaccine Advisory Committee of the National Vaccine Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. georges_peter@brown.edu
authors.forename: G
authors.initials: G
authors.lastname: Peter
authors.forename: M
authors.initials: M
authors.lastname: des Vignes-Kendrick
authors.forename: T C
authors.initials: TC
authors.lastname: Eickhoff
authors.forename: A
authors.initials: A
authors.lastname: Fine
authors.forename: V
authors.initials: V
authors.lastname: Galvin
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
authors.forename: Y A
authors.initials: YA
authors.lastname: Maldonado
authors.forename: E K
authors.initials: EK
authors.lastname: Marcuse
authors.forename: T P
authors.initials: TP
authors.lastname: Monath
authors.forename: J E
authors.initials: JE
authors.lastname: Osborn
authors.forename: S
authors.initials: S
authors.lastname: Plotkin
authors.forename: G A
authors.initials: GA
authors.lastname: Poland
authors.forename: M P
authors.initials: MP
authors.lastname: Quinlisk
authors.forename: D R
authors.initials: DR
authors.lastname: Smith
authors.forename: M
authors.initials: M
authors.lastname: Sokol
authors.forename: D B
authors.initials: DB
authors.lastname: Soland
authors.forename: P N
authors.initials: PN
authors.lastname: Whitley-Williams
authors.forename: D E
authors.initials: DE
authors.lastname: Williamson
authors.forename: R F
authors.initials: RF
authors.lastname: Breiman
mesh_terms: D017277:Drug Approval / Q000458:organization & administration*; D015195:Drug Design; D017408:Guidelines as Topic; D006801:Humans; D012107:Research Design; D014481:United States; D014612:Vaccines
chemical_list: D014612:Vaccines